References:
1. Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017 ; 390(10098):946–958.
2. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010 ; 375(9725):1545–1555.
3. Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis. 2012 ; 54(10):1427–1436.
4. Kramer R, Duclos A, VRS study group in Lyon, Lina B, Casalegno J-S. Cost and burden of RSV related hospitalisation from 2012 to 2017 in the first year of life in Lyon, France. Vaccine. 2018 ; 36(45):6591–6593.
5. Stockman LJ, Curns AT, Anderson LJ, Fischer-Langley G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J.2012 ; 31(1):5–9.
6. Simões EAF, Bont L, Manzoni P, et al. Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children. Infect Dis Ther. 2018 ; 7(1):87–120.
7. Karron RA. Preventing respiratory syncytial virus (RSV) disease in children. Science. 2021 ; 372(6543):686–687.
8. Graham BS. Vaccine development for respiratory syncytial virus. Curr Opin Virol. 2017 ; 23:107–112.
9. Bakker SE, Duquerroy S, Galloux M, et al. The respiratory syncytial virus nucleoprotein–RNA complex forms a left-handed helical nucleocapsid. J Gen Virol. 2013 ; 94(Pt 8):1734–1738.
10. Collins PL, Fearns R, Graham BS. Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. Curr Top Microbiol Immunol. 2013 ; 372:3–38.
11. Abarca K, Rey-Jurado E, Muñoz-Durango N, et al. Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial. EClinicalMedicine. 2020 ; 27:100517.
12. Green CA, Scarselli E, Voysey M, et al. Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults. BMJ Open. 2015 ; 5(10):e008748.
13. Modjarrad K, Giersing B, Kaslow DC, Smith PG, Moorthy VS, WHO RSV Vaccine Consultation Expert Group. WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23-24 March 2015. Vaccine. 2016 ; 34(2):190–197.
14. Jones CE, Calvert A, Le Doare K. Vaccination in Pregnancy-Recent Developments. Pediatr Infect Dis J. 2018 ; 37(2):191–193.
15. Wilcox CR, Holder B, Jones CE. Factors Affecting the FcRn-Mediated Transplacental Transfer of Antibodies and Implications for Vaccination in Pregnancy. Frontiers in Immunology. 2017 ; 8:1294.
16. Eick A, Karron R, Shaw J, et al. The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease. Pediatr Infect Dis J. 2008 ; 27(3):207–212.
17. Stensballe LG, Ravn H, Kristensen K, et al. Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. J Allergy Clin Immunol.2009 ; 123(2):398–403.
18. Buchwald AG, Graham BS, Traore A, et al. RSV neutralizing antibodies at birth predict protection from RSV illness in infants in the first three months of life. Clin Infect Dis. 2020 ; ciaa648.
19. Bulkow LR, Singleton RJ, Karron RA, Harrison LH, Alaska RSV Study Group. Risk factors for severe respiratory syncytial virus infection among Alaska native children. Pediatrics. 2002 ; 109(2):210–216.
20. Nyiro JU, Sande CJ, Mutunga M, et al. Absence of Association between Cord Specific Antibody Levels and Severe Respiratory Syncytial Virus (RSV) Disease in Early Infants: A Case Control Study from Coastal Kenya. PLoS One. 2016 ; 11(11):e0166706.
21. Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012 ; 379(9832):2162–2172.
22. Kramer MS, Papageorghiou A, Culhane J, et al. Challenges in defining and classifying the preterm birth syndrome. Am J Obstet Gynecol.2012 ; 206(2):108–112.
23. Giersing BK, Karron RA, Vekemans J, Kaslow DC, Moorthy VS. Meeting report: WHO consultation on Respiratory Syncytial Virus (RSV) vaccine development, Geneva, 25-26 April 2016. Vaccine. 2019 ; 37(50):7355–7362.
24. Capella C, Chaiwatpongsakorn S, Gorrell E, et al. Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection. J Infect Dis.2017 ; 216(11):1398–1406.
25. Buchwald AG, Graham BS, Traore A, et al. RSV neutralizing antibodies at birth predict protection from RSV illness in infants in the first three months of life. Clin Infect Dis. 2020 ; ciaa248.
26. Gaymard A, Bouscambert-Duchamp M, Pichon M, et al. Genetic characterization of respiratory syncytial virus highlights a new BA genotype and emergence of the ON1 genotype in Lyon, France, between 2010 and 2014. J Clin Virol. 2018 ; 102:12–18.
27. Roux X, Dubuquoy C, Durand G, et al. Sub-nucleocapsid nanoparticles: a nasal vaccine against respiratory syncytial virus. PLoS One.2008 ; 3(3):e1766.
28. Linder N, Ohel G. In utero vaccination. Clin Perinatol.1994 ; 21(3):663–674.
29. Mammas IN, Drysdale SB, Rath B, et al. Update on current views and advances on RSV infection (Review). Int J Mol Med. 2020 ; 46(2):509–520.
30. Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol. 1996 ; 36(5):248–255.
31. Homaira N, Mallitt K-A, Oei J-L, et al. Risk factors associated with RSV hospitalisation in the first 2 years of life, among different subgroups of children in NSW: a whole-of-population-based cohort study. BMJ Open. 2016 ; 6(6):e011398.
32. Bont L, Checchia PA, Fauroux B, et al. Defining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western Countries. Infect Dis Ther. 2016 ; 5(3):271–298.
33. Aikphaibul P, Theerawit T, Sophonphan J, Wacharachaisurapol N, Jitrungruengnij N, Puthanakit T. Risk factors of severe hospitalized respiratory syncytial virus infection in tertiary care center in Thailand. Influenza Other Respir Viruses. 2021 ; 15(1):64–71.